A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs EYP 001 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors ENYO Pharma
  • Most Recent Events

    • 13 Jun 2017 According to an ENYO Pharma media release, data from the study has been presented at the international liver conference.
    • 13 Jun 2017 Results published in an ENYO Pharma media release.
    • 06 Apr 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top